Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in BRCA Carriers

被引:81
作者
Beattie, Mary S. [1 ,2 ,3 ]
Crawford, Beth [2 ]
Lin, Feng [3 ]
Vittinghoff, Eric [3 ]
Ziegler, John [2 ,3 ]
机构
[1] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr Comprehens Canc, Canc Risk Program, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
关键词
OVARIAN-CANCER SUSCEPTIBILITY; BREAST-CANCER; SALPINGO-OOPHORECTOMY; PROPHYLACTIC SURGERY; MUTATION CARRIERS; PREVENTIVE STRATEGIES; INHERITED MUTATIONS; GENETIC RISK; WOMEN; SURVEILLANCE;
D O I
10.1089/gtmb.2008.0067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction and Aims: For women who carry BRCA mutations, risk-reducing surgeries are an option to decrease breast and ovarian cancer risk. This study aims to determine the uptake, time course, and predictors of risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) in BRCA carriers. Results: In 272 female carriers, followed for a median of 3.7 years, 23% of those eligible chose RRM, and 51% percent chose RRSO. Among BRCA carriers who chose these procedures, median time to both RRM and RRSO was approximately 4 months after learning of BRCA-positive results. Predictors of RRM were as follows: age below 60 years (hazard ratio 1.8, p = 0.04), prior breast cancer (hazard ratio 2.4, p = 0.0004), and RRSO ( hazard ratio 7.2, p < 0.0001). Predictors of RRSO were as follows: age below 60 years (hazard ratio 3.6, p = 0.006), prior breast cancer (hazard ratio 1.8, p = 0.002), and RRM (hazard ratio 5.4, p < 0.0001). Conclusions: Many women who undergo BRCA testing use these results to make clinical decisions; those who choose risk-reducing surgeries typically do so within months of receiving BRCA-positive results. Predictors of risk-reducing surgery uptake include the following: age below 60 years, prior breast cancer, and utilization of another risk-reducing surgery. Future research directions include examining other preventive and screening options in BRCA carriers as well as studying motivations for choosing or declining risk-reducing surgeries.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 37 条
[1]   Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation [J].
Anderson, K ;
Jacobson, JS ;
Heitjan, DF ;
Zivin, JG ;
Hershman, D ;
Neugut, AI ;
Grann, VR .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (06) :397-406
[2]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[3]   Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers:: A systematic review [J].
Bermejo-Perez, M. J. ;
Marquez-Calderon, S. ;
Llanos-Mendez, A. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (02) :225-231
[4]   Genetic testing for a BRCA1 mutation:: Prophylactic surgery and screening behavior in women 2 years post testing [J].
Botkin, JR ;
Smith, KR ;
Croyle, RT ;
Baty, BJ ;
Wylie, JE ;
Dutson, D ;
Chan, A ;
Hamann, HA ;
Lerman, C ;
McDonald, J ;
Venne, V ;
Ward, JH ;
Lyon, E .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2003, 118A (03) :201-209
[5]   Incidence of second primary breast cancer among women with a first primary in Manitoba, Canada [J].
Chen, Y ;
Semenciw, R ;
Kliewer, E ;
Shi, YL ;
Mao, Y .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 67 (01) :35-40
[6]   Preparing for personalized medicine [J].
Chopra, SS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (13) :1640-1640
[7]   Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[8]   RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].
FORD, D ;
EASTON, DF ;
BISHOP, DT ;
NAROD, SA ;
GOLDGAR, DE ;
HAITES, N ;
MILNER, B ;
ALLAN, L ;
PONDER, BAJ ;
PETO, J ;
SMITH, S ;
STRATTON, M ;
LENOIR, GM ;
FEUNTEUN, J ;
LYNCH, H ;
ARASON, A ;
BARKARDOTTIR, R ;
EGILSSON, V ;
BLACK, DM ;
KELSELL, D ;
SPURR, N ;
DEVILEE, P ;
CORNELISSE, CJ ;
VARSEN, H ;
BIRCH, JM ;
SKOLNICK, M ;
SANTIBANEZKOREF, MS ;
TEARE, D ;
STEEL, M ;
PORTER, D ;
COHEN, BB ;
CAROTHERS, A ;
SMYTH, E ;
WEBER, B ;
NEWBOLD, B ;
BOEHNKE, M ;
COLLINS, FS ;
CANNONALBRIGHT, LA ;
GOLDGAR, D .
LANCET, 1994, 343 (8899) :692-695
[9]  
Grann VR, 2002, J CLIN ONCOL, V20, P2520, DOI 10.1200/JCO.2002.10.101
[10]   A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: Design and baseline characteristics: A Gynecologic oncology group study [J].
Greene, Mark H. ;
Piedmonte, Marion ;
Alberts, Dave ;
Gail, Mitchell ;
Hensley, Martee ;
Miner, Zoe ;
Mai, Phuong L. ;
Loud, Jennifer ;
Rodriguez, Gustavo ;
Basil, Jack ;
Boggess, John ;
Schwartz, Peter E. ;
Kelley, Joseph L. ;
Wakeley, Katie E. ;
Minasian, Lori ;
Skates, Stephen .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (03) :594-604